April 10, 2025 10:40 AM EDTUpdated 05:20 PM

Alzheon’s amyloid-targeting pill fails another Phase 3 study in Alzheimer’s

Ryan Cross

Senior Science Correspondent

Alzheon’s controversial, decade-long bet that a failed Alzheimer’s drug could offer bigger benefits to a subset of patients at the highest risk for the disease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Alzheon’s amyloid-targeting pill fails another Phase 3 study in Alzheimer’s

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Market turmoil is tanking biotech M&A and IPOs. Here's the playbook startups will use to survive

Makary wants to replace animal testing with organoids. It may take a while

Recruiters say some biopharmas pause hiring as they struggle to make sense of ongoing uncertainty

Pharma tariffs: Here’s what a potential rollout could look like

Exclusive: Merida Biosciences gets $121M to treat autoimmune and allergy diseases at their roots

Bristol Myers' immunotherapy combo nets approvals in colorectal and liver cancer

Alzheon’s amy­loid-tar­get­ing pill fails an­oth­er Phase 3 study in Alzheimer’s

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

more like this

Mar­ket tur­moil is tank­ing biotech M&A and IPOs. Here's the play­book star­tups will use to sur­vive

Makary wants to re­place an­i­mal test­ing with organoids. It may take a while

Re­cruiters say some bio­phar­mas pause hir­ing as they strug­gle to make sense of on­go­ing un­cer­tain­ty

Phar­ma tar­iffs: Here’s what a po­ten­tial roll­out could look like

Ex­clu­sive: Meri­da Bio­sciences gets $121M to treat au­toim­mune and al­ler­gy dis­eases at their roots

Bris­tol My­er­s' im­munother­a­py com­bo nets ap­provals in col­orec­tal and liv­er can­cer

Alzheon’s amyloid-targeting pill fails another Phase 3 study in Alzheimer’s

Market turmoil is tanking biotech M&A and IPOs. Here's the playbook startups will use to survive

Makary wants to replace animal testing with organoids. It may take a while

Recruiters say some biopharmas pause hiring as they struggle to make sense of ongoing uncertainty

Pharma tariffs: Here’s what a potential rollout could look like

Exclusive: Merida Biosciences gets $121M to treat autoimmune and allergy diseases at their roots

Bristol Myers' immunotherapy combo nets approvals in colorectal and liver cancer